首页 > 最新文献

Journal of Psoriasis and Psoriatic Arthritis最新文献

英文 中文
Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab. 英夫利昔单抗和乌斯特金单抗联合生物治疗顽固性银屑病缓解的勘误表
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195884

[This corrects the article DOI: 10.1177/24755303211029598.].

[此处更正了文章 DOI:10.1177/24755303211029598]。
{"title":"Corrigendum to Remission of Recalcitrant Psoriasis on Combined Biologic Therapy With Infliximab and Ustekinumab.","authors":"","doi":"10.1177/24755303231195884","DOIUrl":"10.1177/24755303231195884","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/24755303211029598.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"197"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47487371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting Proceedings. 银屑病和银屑病关节炎临床多中心促进网络联盟(PPAACMAN)2021年会论文集
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-09 DOI: 10.1177/24755303231195967
Carly Grant, Lourdes Perez-Chada, Rebecca H Haberman, Daniel Webster, Oliver FitzGerald, Christopher Ritchlin, Vinod Chandran, Cheryl F Rosen, Brittany Weber, Michael Garshick, Lihi Eder, Soumya M Reddy, Alexis Ogdie, Jose U Scher, Joseph F Merola

The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) is a nonprofit organization whose mission is to optimize the clinical care of patients with psoriatic disease through multidisciplinary collaboration models. The PPACMAN 2021 Annual Meeting was held virtually on December 11, 2021. In all, 50 stakeholders participated in the meeting including dermatologists, rheumatologists, cardiologists, clinical researchers, patient advocacy representatives, and industry representatives. During the opening session of the meeting, presenters provided an update of several research projects dedicated to predicting and preventing psoriatic arthritis (PsA) such as the Psorcast, PAMPA, HIPPOCRATES, and the ELLIPSS studies. The second session centered around novel approaches to deliver multidisciplinary care in psoriatic disease. PPACMAN leadership introduced its wellness program and invited speakers to discuss new advances in cardiovascular disease, sleep disturbance, mental health problems, and dietary interventions in psoriatic disease. The final session of the meeting focused on how to improve patient engagement in their disease and care.

银屑病和银屑病关节炎诊所多中心推进网络(PPACMAN)是一个非营利性组织,其使命是通过多学科合作模式优化银屑病患者的临床护理。PPACMAN 2021年年会于2021年12月11日举行。总共有50名利益相关者参加了会议,包括皮肤科医生、风湿病专家、心脏病专家、临床研究人员、患者权益代表和行业代表。在会议的开幕式上,演讲者提供了几个致力于预测和预防银屑病关节炎(PsA)的研究项目的最新进展,如Psorcast、PAMPA、HIPPOCRATES和ELLIPSS研究。第二部分围绕银屑病多学科治疗的新方法展开。PPACMAN领导介绍了其健康计划,并邀请演讲者讨论了心血管疾病、睡眠障碍、心理健康问题和银屑病饮食干预的新进展。会议的最后一场会议重点讨论了如何提高患者对其疾病和护理的参与度。
{"title":"Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) 2021 Annual Meeting Proceedings.","authors":"Carly Grant, Lourdes Perez-Chada, Rebecca H Haberman, Daniel Webster, Oliver FitzGerald, Christopher Ritchlin, Vinod Chandran, Cheryl F Rosen, Brittany Weber, Michael Garshick, Lihi Eder, Soumya M Reddy, Alexis Ogdie, Jose U Scher, Joseph F Merola","doi":"10.1177/24755303231195967","DOIUrl":"10.1177/24755303231195967","url":null,"abstract":"<p><p>The Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network (PPACMAN) is a nonprofit organization whose mission is to optimize the clinical care of patients with psoriatic disease through multidisciplinary collaboration models. The PPACMAN 2021 Annual Meeting was held virtually on December 11, 2021. In all, 50 stakeholders participated in the meeting including dermatologists, rheumatologists, cardiologists, clinical researchers, patient advocacy representatives, and industry representatives. During the opening session of the meeting, presenters provided an update of several research projects dedicated to predicting and preventing psoriatic arthritis (PsA) such as the Psorcast, PAMPA, HIPPOCRATES, and the ELLIPSS studies. The second session centered around novel approaches to deliver multidisciplinary care in psoriatic disease. PPACMAN leadership introduced its wellness program and invited speakers to discuss new advances in cardiovascular disease, sleep disturbance, mental health problems, and dietary interventions in psoriatic disease. The final session of the meeting focused on how to improve patient engagement in their disease and care.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"179-183"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43463336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities. 伴有代谢合并症的银屑病患者生物停药比例的勘误表
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-23 DOI: 10.1177/24755303231195867

[This corrects the article DOI: 10.1177/24755303221131257.].

[此处更正了文章 DOI:10.1177/24755303221131257]。
{"title":"Corrigendum to Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities.","authors":"","doi":"10.1177/24755303231195867","DOIUrl":"10.1177/24755303231195867","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/24755303221131257.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"198"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48857307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis. 更正一例Brodalumab治疗银屑病继发Grover病
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195863

[This corrects the article DOI: 10.1177/2475530320970530.].

[此处更正了文章 DOI:10.1177/2475530320970530]。
{"title":"Corrigendum to A Case of Grover's Disease Secondary to Brodalumab Therapy for Psoriasis.","authors":"","doi":"10.1177/24755303231195863","DOIUrl":"10.1177/24755303231195863","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/2475530320970530.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"188"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46427826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Systematic Review of Follicular Psoriasis: A Unique but Under-Recognized Entity. 毛囊性银屑病的系统评价:一种独特但未被充分认识的实体
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-24 DOI: 10.1177/24755303231196567
Kelli Jablon, Jonathan D Ho, Hye Jin Chung

Background: Follicular psoriasis (FP) is a rare and under-recognized subtype of psoriasis that affects hair follicles and can be frequently misdiagnosed due to its unique presentation.

Objective: We aimed to analyze the frequently reported clinical, histological, and dermatoscopic features of FP, as well as their treatment options.

Methods: We conducted a systematic review of the PubMed/MEDLINE database using the search terms "follicular" and "psoriasis." Fourteen studies were included yielding information on 44 patients (27 adults [61.4%] and 17 children [38.6%]).

Results: Adult FP showed a female predominance (M:F = 1:2.7), frequent involvement of lower extremities (81.5%), association with metabolic syndrome including diabetes mellitus (22.2%), and a predilection for skin of color (SOC:White = 8:1). On the contrary, juvenile FP revealed male predominance (M:F = 1:0.6), frequent involvement of the trunk (41.2%), and exclusive involvement in skin of color (SOC:White = 11:0). In addition to its unique presentation, FP tends to be misdiagnosed due to its low incidence of concomitant psoriasis (31.8%), and rare personal (18.2%) or family history (6.8%) of psoriasis. Reported histopathological features include keratotic plugging, follicular parakeratosis with or without neutrophils, psoriasiform acanthosis, hypogranulosis, and neutrophilic infiltration of follicular epithelium. Dermatoscopic findings include folliculocentric lesions with normal appearing terminal hairs, perifollicular white scale, and various vascular structures.

Conclusion: Once correctly diagnosed, patients with FP showed improvement or resolution of symptoms with various combinations of topical and systemic therapies. Understanding the demographic features and clinical presentations of FP can help address under-recognition of this clinical variant of psoriasis.

毛囊性牛皮癣(FP)是一种罕见且未被充分认识的牛皮癣亚型,它影响毛囊,由于其独特的表现,经常被误诊。我们的目的是分析经常报道的FP的临床、组织学和皮肤镜特征,以及他们的治疗方案。我们对PubMed/MEDLINE数据库进行了系统的检索,检索词为“滤泡性”和“牛皮癣”。14项研究纳入了44例患者(27例成人[61.4%]和17例儿童[38.6%])的信息。成年FP以女性为主(M:F = 1:7 .7),经常累及下肢(81.5%),与代谢综合征(包括糖尿病)相关(22.2%),偏爱有色皮肤(SOC:白色= 8:1)。相反,幼年型FP表现为雄性优势(M:F = 1:6 .6),常累及躯干(41.2%),只累及有色皮肤(SOC:White = 11:0)。除了其独特的表现外,由于其伴发牛皮癣的发生率低(31.8%),以及罕见的个人(18.2%)或家族史(6.8%),FP容易被误诊。报告的组织病理学特征包括角化性堵塞,滤泡角化不全伴或不伴中性粒细胞,牛皮癣状棘层病,低颗粒病和滤泡上皮中性粒细胞浸润。皮镜检查结果包括毛囊中心病变,终末毛外观正常,毛囊周围白色鳞片和各种血管结构。一旦正确诊断,FP患者通过局部和全身治疗的各种组合表现出症状的改善或缓解。了解FP的人口学特征和临床表现可以帮助解决对这种牛皮癣临床变体的认识不足。
{"title":"A Systematic Review of Follicular Psoriasis: A Unique but Under-Recognized Entity.","authors":"Kelli Jablon, Jonathan D Ho, Hye Jin Chung","doi":"10.1177/24755303231196567","DOIUrl":"10.1177/24755303231196567","url":null,"abstract":"<p><strong>Background: </strong>Follicular psoriasis (FP) is a rare and under-recognized subtype of psoriasis that affects hair follicles and can be frequently misdiagnosed due to its unique presentation.</p><p><strong>Objective: </strong>We aimed to analyze the frequently reported clinical, histological, and dermatoscopic features of FP, as well as their treatment options.</p><p><strong>Methods: </strong>We conducted a systematic review of the PubMed/MEDLINE database using the search terms \"follicular\" and \"psoriasis.\" Fourteen studies were included yielding information on 44 patients (27 adults [61.4%] and 17 children [38.6%]).</p><p><strong>Results: </strong>Adult FP showed a female predominance (M:F = 1:2.7), frequent involvement of lower extremities (81.5%), association with metabolic syndrome including diabetes mellitus (22.2%), and a predilection for skin of color (SOC:White = 8:1). On the contrary, juvenile FP revealed male predominance (M:F = 1:0.6), frequent involvement of the trunk (41.2%), and exclusive involvement in skin of color (SOC:White = 11:0). In addition to its unique presentation, FP tends to be misdiagnosed due to its low incidence of concomitant psoriasis (31.8%), and rare personal (18.2%) or family history (6.8%) of psoriasis. Reported histopathological features include keratotic plugging, follicular parakeratosis with or without neutrophils, psoriasiform acanthosis, hypogranulosis, and neutrophilic infiltration of follicular epithelium. Dermatoscopic findings include folliculocentric lesions with normal appearing terminal hairs, perifollicular white scale, and various vascular structures.</p><p><strong>Conclusion: </strong>Once correctly diagnosed, patients with FP showed improvement or resolution of symptoms with various combinations of topical and systemic therapies. Understanding the demographic features and clinical presentations of FP can help address under-recognition of this clinical variant of psoriasis.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"141-147"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46660247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring. 银屑病指甲变化更正:甲癣镜检查与NAPSI评分的相关性
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195872

[This corrects the article DOI: 10.1177/24755303211011477.].

[此处更正了文章 DOI:10.1177/24755303211011477]。
{"title":"Corrigendum to Nail Changes in Psoriasis: Correlation Between Onychoscopy and NAPSI Scoring.","authors":"","doi":"10.1177/24755303231195872","DOIUrl":"10.1177/24755303231195872","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/24755303211011477.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"200"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46980484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation Between Insulin Resistance and Psoriatic Arthritis Disease Activity: A Cross-Sectional Study. 胰岛素抵抗与银屑病关节炎活动性的相关性研究
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-05-31 DOI: 10.1177/24755303231180508
Yuliasih Yuliasih, Martino Handoyo, Lita Diah Rahmawati, Sony Wibisono, Nabilatun Nisa

Objectives: Most psoriatic arthritis (PsA) research and studies focus solely on the skin and joint manifestations, but there is also an increased risk of metabolic disorders, including insulin resistance (IR). This study aims to discover the relationship between IR and disease activity (DA) in PsA and its phenotype.

Materials and methods: Patients with PsA classified using the CASPAR criteria with the disease activity was measured using the DAPSA score, and IR was identified as an elevated HOMA-IR of >2.5. The disease phenotype was determined with Moll and Wright's classification of the PsA subtype. The Pearson correlation test examined the relationship between DA and IR. The descriptive analysis was conducted to determine the relationship between the DAPSA score and HOMA-IR value in each PsA phenotype. All tests were two-tailed, analysed with GraphPad Prism 9, and a P-value of less than .05 was considered statistically significant.

Results: From thirty-one patients, there was a strong and positive relationship between DA and IR (r = .768, P = .000). We also observed variations in DAPSA score and HOMA-IR value across different phenotypes, with symmetrical polyarthritis exhibiting the highest DAPSA score (21.55 ± 3.50) and HOMA-IR value (2.913 ± .5392) despite asymmetrical oligoarthritis that being the most frequent phenotype.

Conclusion: Our study revealed a significant association between disease activity and insulin resistance in PsA patients, with the symmetrical polyarthritis phenotype demonstrating the highest levels of DAPSA score and IR value. This finding allowed rheumatologists to behold this manifestation and could improve PsA patients' long-term outlook.

目的:大多数银屑病关节炎(PsA)的研究仅集中在皮肤和关节表现上,但代谢紊乱的风险也会增加,包括胰岛素抵抗(IR)。本研究旨在发现PsA及其表型中IR与疾病活性(DA)之间的关系。材料和方法:使用疾病活动性的CASPAR标准分类的PsA患者使用DAPSA评分进行测量,IR被确定为HOMA-IR升高>2.5。根据Moll和Wright对PsA亚型的分类来确定疾病表型。Pearson相关检验检验了DA和IR之间的关系。进行描述性分析以确定每个PsA表型中DAPSA评分和HOMA-IR值之间的相关性。所有测试都是双尾的,用GraphPad Prism 9进行分析,P值小于0.05被认为具有统计学意义。结果:在31例患者中,DA和IR之间存在强烈的正相关关系(r=.768,P=.000)。我们还观察到不同表型的DAPSA评分和HOMA-IR值的变化,对称性多关节炎表现出最高的DAPSA评分(21.55±3.50)和HOMA-IR值(2.913±.5392),尽管不对称性寡关节炎是最常见的表型。结论:我们的研究揭示了PsA患者的疾病活动性与胰岛素抵抗之间的显著相关性,对称性多关节炎表型的DAPSA评分和IR值最高。这一发现使风湿病学家能够观察到这种表现,并可以改善PsA患者的长期前景。
{"title":"Correlation Between Insulin Resistance and Psoriatic Arthritis Disease Activity: A Cross-Sectional Study.","authors":"Yuliasih Yuliasih, Martino Handoyo, Lita Diah Rahmawati, Sony Wibisono, Nabilatun Nisa","doi":"10.1177/24755303231180508","DOIUrl":"10.1177/24755303231180508","url":null,"abstract":"<p><strong>Objectives: </strong>Most psoriatic arthritis (PsA) research and studies focus solely on the skin and joint manifestations, but there is also an increased risk of metabolic disorders, including insulin resistance (IR). This study aims to discover the relationship between IR and disease activity (DA) in PsA and its phenotype.</p><p><strong>Materials and methods: </strong>Patients with PsA classified using the CASPAR criteria with the disease activity was measured using the DAPSA score, and IR was identified as an elevated HOMA-IR of >2.5. The disease phenotype was determined with Moll and Wright's classification of the PsA subtype. The Pearson correlation test examined the relationship between DA and IR. The descriptive analysis was conducted to determine the relationship between the DAPSA score and HOMA-IR value in each PsA phenotype. All tests were two-tailed, analysed with GraphPad Prism 9, and a <i>P</i>-value of less than .05 was considered statistically significant.</p><p><strong>Results: </strong>From thirty-one patients, there was a strong and positive relationship between DA and IR (r = .768, <i>P</i> = .000). We also observed variations in DAPSA score and HOMA-IR value across different phenotypes, with symmetrical polyarthritis exhibiting the highest DAPSA score (21.55 ± 3.50) and HOMA-IR value (2.913 ± .5392) despite asymmetrical oligoarthritis that being the most frequent phenotype.</p><p><strong>Conclusion: </strong>Our study revealed a significant association between disease activity and insulin resistance in PsA patients, with the symmetrical polyarthritis phenotype demonstrating the highest levels of DAPSA score and IR value. This finding allowed rheumatologists to behold this manifestation and could improve PsA patients' long-term outlook.</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"129-133"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47232369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey. 银屑病患者接种COVID-19疫苗的可能性的勘误表:来自大型现实世界调查的结果
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-23 DOI: 10.1177/24755303231195873

[This corrects the article DOI: 10.1177/24755303211067822.].

[此处更正了文章 DOI:10.1177/24755303211067822]。
{"title":"Corrigendum to Likelihood of COVID-19 Vaccination Among Individuals Living With Psoriatic Disease: Results From a Large Real-World Survey.","authors":"","doi":"10.1177/24755303231195873","DOIUrl":"10.1177/24755303231195873","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/24755303211067822.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"185"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45407907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options. 掌跖脓疱病的实践模式的勘误表:患者人口统计和治疗方案
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-23 DOI: 10.1177/24755303231195875

[This corrects the article DOI: 10.1177/24755303221099292.].

[此处更正了文章 DOI:10.1177/24755303221099292]。
{"title":"Corrigendum to Practice Patterns of Palmoplantar Pustulosis: Patient Demographics and Treatment Options.","authors":"","doi":"10.1177/24755303231195875","DOIUrl":"10.1177/24755303231195875","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/24755303221099292.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"199"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361553/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48398559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series. Ixekizumab成功治疗口腔银屑病的更正:一系列病例
Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-08-31 DOI: 10.1177/24755303231195862

[This corrects the article DOI: 10.1177/2475530320970538.].

[此处更正了文章 DOI:10.1177/2475530320970538]。
{"title":"Corrigendum to Successful Treatment of Guttate Psoriasis With Ixekizumab: A Case Series.","authors":"","doi":"10.1177/24755303231195862","DOIUrl":"10.1177/24755303231195862","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1177/2475530320970538.].</p>","PeriodicalId":36656,"journal":{"name":"Journal of Psoriasis and Psoriatic Arthritis","volume":" ","pages":"196"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11361541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47449195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Psoriasis and Psoriatic Arthritis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1